In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Berencsi, Klara ^a   Rani, Pyapalli ^a   Zhang, Tianqian ^a   Gross, Laura ^a   Mastrangelo, Michael ^b   Meropol, Neal J ^c,d   Herlyn, Dorothee ^a   Somasundaram, Rajasekharan ^a  

^a WISTAR INSTITUTE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; COLLAGEN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; CCL2 PROTEIN, HUMAN; CCR2 PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INFILTRATION; CHEMOTAXIS; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FETUS; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MIGRATION INHIBITION; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SECRETION; ANIMAL; CELL MOTION; COLON TUMOR; METABOLISM; PATHOLOGY; PHENOTYPE; TIME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL2; COLONIC NEOPLASMS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; PHENOTYPE; RECEPTORS, CCR2; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953073898     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-33     Document Type: Article

References (58)

1. Somasundaram R, Herlyn D. Chemokines and the microenvironment in neuroectodermal tumor-host interaction. Semin Cancer Biol 2009, 19:92-96. 10.1016/j.semcancer.2008.11.002, 2806055, 19049876.
2. Luster AD. Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med 1998, 338:436-445. 10.1056/NEJM199802123380706, 9459648.
3. Baggiolini M. Chemokines in pathology and medicine. J Intern Med 2001, 250:91-104. 10.1046/j.1365-2796.2001.00867.x, 11489059.
4. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol 2001, 2:95-101. 10.1038/84298, 11175800.
5. Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang LC, Heitjan D, Snyder LA, Albelda SM. CCL2 blockade augments cancer immunotherapy. Cancer Res 70:109-118. 10.1158/0008-5472.CAN-09-2326, 2821565, 20028856.
6. Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 2002, 118:915-922. 10.1046/j.1523-1747.2002.01725.x, 12060384.
7. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007, 256:137-165. 10.1016/j.canlet.2007.05.013, 2065851, 17629396.
8. Ghadjar P, Rubie C, Aebersold DM, Keilholz U. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer 2009, 125:741-745. 10.1002/ijc.24468, 19480006.
9. Akishima-Fukasawa Y, Nakanishi Y, Ino Y, Moriya Y, Kanai Y, Hirohashi S. Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. Am J Clin Pathol 2009, 132:202-210. quiz 307, 10.1309/AJCPK35VZJEWCUTL, 19605814.
10. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 2007, 67:9417-9424. 10.1158/0008-5472.CAN-07-1286, 17909051.
11. Frederick MJ, Clayman GL. Chemokines in cancer. Expert Rev Mol Med 2001, 3:1-18. 10.1017/S1462399401003301, 14585143.
12. Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer?. Nat Rev Immunol 2002, 2:175-184. 10.1038/nri748, 11913068.
13. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002, 13:143-154. 10.1016/S1359-6101(01)00033-8, 11900990.
14. Erreni M, Bianchi P, Laghi L, Mirolo M, Fabbri M, Locati M, Mantovani A, Allavena P. Expression of chemokines and chemokine receptors in human colon cancer. Methods Enzymol 2009, 460:105-121. full_text, 19446722.
15. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139, 17008531.
16. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-2666. 10.1056/NEJMoa051424, 16371631.
17. Musha H, Ohtani H, Mizoi T, Kinouchi M, Nakayama T, Shiiba K, Miyagawa K, Nagura H, Yoshie O, Sasaki I. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer 2005, 116:949-956. 10.1002/ijc.21135, 15856455.
18. Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 2005, 26:41-47.
19. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F, Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71:1263-1271. 10.1158/0008-5472.CAN-10-2907, 21303976.
20. Baier PK, Eggstein S, Wolff-Vorbeck G, Baumgartner U, Hopt UT. Chemokines in human colorectal carcinoma. Anticancer Res 2005, 25:3581-3584.
21. Bailey C, Negus R, Morris A, Ziprin P, Goldin R, Allavena P, Peck D, Darzi A. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis 2007, 24:121-130. 10.1007/s10585-007-9060-3, 17390111.
22. Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, Pasquali C, Calori G, Pessi F, Sperti C, Di Carlo V, Allavena P, Piemonti L. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 2003, 63:7451-7461.
23. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001, 166:6483-6490.
24. Huang S, Singh RK, Xie K, Gutman M, Berry KK, Bucana CD, Fidler IJ, Bar-Eli M. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immunother 1994, 39:231-238. 10.1007/BF01525986, 7954525.
25. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004, 4:11-22. 10.1038/nrc1252, 14708024.
26. Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH, Broxmeyer HE, Cornetta K. The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 2000, 164:4025-4031.
27. Fushimi T, O'Connor TP, Crystal RG. Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Res 2006, 66:3513-3522. 10.1158/0008-5472.CAN-05-1493, 16585175.
28. Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, Batra RK, Dubinett SM. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000, 164:4558-4563.
29. Mitchell MS, Darrah D, Yeung D, Halpern S, Wallace A, Voland J, Jones V, Kan-Mitchell J. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 2002, 20:1075-1086. 10.1200/JCO.20.4.1075, 11844833.
30. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O'Brien-Jenkins A, Gimotty PA, Coukos G. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008, 14:28-36. 10.1038/nm1699, 18157142.
31. Penichet ML, Morrison SL. Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 2001, 248:91-101. 10.1016/S0022-1759(00)00345-8, 11223071.
32. Berencsi K, Meropol NJ, Hoffman JP, Sigurdson E, Giles L, Rani P, Somasundaram R, Zhang T, Kalabis J, Caputo L, Furth E, Swoboda R, Marincola F, Herlyn D. Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Cancer Immunol Immunother 2007, 56:359-370. 10.1007/s00262-006-0190-2, 16783574.
33. Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, Birebent B, Bloome E, Kim J, Berencsi K, Mastrangelo M, Herlyn D. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 2002, 62:5267-5272.
34. Zhang T, Somasundaram R, Berencsi K, Caputo L, Gimotty P, Rani P, Guerry D, Swoboda R, Herlyn D. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol 2006, 36:457-467. 10.1002/eji.200526208, 16421945.
35. Felgar RE, Furth EE, Wasik MA, Gluckman SJ, Salhany KE. Histiocytic necrotizing lymphadenitis (Kikuchi's disease): in situ end-labeling, immunohistochemical, and serologic evidence supporting cytotoxic lymphocyte-mediated apoptotic cell death. Mod Pathol 1997, 10:231-241.
36. Friedl P, Entschladen F, Conrad C, Niggemann B, Zanker KS. CD4+ T lymphocytes migrating in three-dimensional collagen lattices lack focal adhesions and utilize beta1 integrin-independent strategies for polarization, interaction with collagen fibers and locomotion. Eur J Immunol 1998, 28:2331-2343. 10.1002/(SICI)1521-4141(199808)28:08<2331::AID-IMMU2331>3.0.CO;2-C, 9710211.
37. Rao WH, Hales JM, Camp RD. Potent costimulation of effector T lymphocytes by human collagen type I. J Immunol 2000, 165:4935-4940.
38. Aiba S, Nakagawa S, Hara M, Tomioka Y, Deguchi M, Tagami H. Cultured murine dermal cells can function like thymic nurse cells. J Invest Dermatol 1994, 103:162-167. 10.1111/1523-1747.ep12392632, 7518855.
39. Murakami S, Okada H. Lymphocyte-fibroblast interactions. Crit Rev Oral Biol Med 1997, 8:40-50. 10.1177/10454411970080010201, 9063624.
40. Crowston JG, Salmon M, Khaw PT, Akbar AN. T-lymphocyte-fibroblast interactions. Biochem Soc Trans 1997, 25:529-531.
41. Maas-Szabowski N, Stark HJ, Fusenig NE. Keratinocyte growth regulation in defined organotypic cultures through IL-1-induced keratinocyte growth factor expression in resting fibroblasts. J Invest Dermatol 2000, 114:1075-1084. 10.1046/j.1523-1747.2000.00987.x, 10844548.
42. Maaser K, Wolf K, Klein CE, Niggemann B, Zanker KS, Brocker EB, Friedl P. Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices. Mol Biol Cell 1999, 10:3067-3079. 25559, 10512851.
43. Binnerts ME, van Kooyk Y, Simmons DL, Figdor CG. Distinct binding of T lymphocytes to ICAM-1, -2 or -3 upon activation of LFA-1. Eur J Immunol 1994, 24:2155-2160. 10.1002/eji.1830240933, 7916295.
44. Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P, Guerry D, Furth E, Rollins BJ, Putt M, Gimotty P, Swoboda R, Herlyn M, Herlyn D. CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J Immunol 2005, 174:5856-5863.
45. Starnes HF. Biological effects and possible clinical applications of interleukin 1. Semin Hematol 1991, 28:34-41.
46. Rathmell JC, Farkash EA, Gao W, Thompson CB. IL-7 enhances the survival and maintains the size of naive T cells. J Immunol 2001, 167:6869-6876.
47. Wei WZ, Miller B, Gutierrez RM. Inhibition of tumor growth by peptide specific cytotoxic T lymphocytes in a three-dimensional collagen matrix. J Immunol Methods 1997, 200:47-54. 10.1016/S0022-1759(96)00196-2, 9005943.
48. Jacobs N, Moutschen MP, Franzen-Detrooz E, Boniver V, Boniver J, Delvenne P. Organotypic culture of HPV-transformed keratinocytes: a model for testing lymphocyte infiltration of (pre)neoplastic lesions of the uterine cervix. Virchows Arch 1998, 432:323-330. 10.1007/s004280050173, 9565341.
49. Tasaki A, Yamanaka N, Kubo M, Matsumoto K, Kuroki H, Nakamura K, Nakahara C, Onishi H, Kuga H, Baba E, Tanaka M, Morisaki T, Katano M. Three-dimensional two-layer collagen matrix gel culture model for evaluating complex biological functions of monocyte-derived dendritic cells. J Immunol Methods 2004, 287:79-90. 10.1016/j.jim.2004.01.014, 15099757.
50. Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, Jensen MC. Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol 2007, 179:3332-3341.
51. Zibert A, Balzer S, Souquet M, Quang TH, Paris-Scholz C, Roskrow M, Dilloo D. CCL3/MIP-1alpha is a potent immunostimulator when coexpressed with interleukin-2 or granulocyte-macrophage colony-stimulating factor in a leukemia/lymphoma vaccine. Hum Gene Ther 2004, 15:21-34. 10.1089/10430340460732436, 14965375.
52. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999, 17:253-258. 10.1038/6995, 10096292.
53. Biragyn A, Kwak LW. Designer cancer vaccines are still in fashion. Nat Med 2000, 6:966-968. 10.1038/79649, 10973307.
54. Guidoboni M, Gafa R, Viel A, Doglioni C, Russo A, Santini A, Del Tin L, Macri E, Lanza G, Boiocchi M, Dolcetti R. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 2001, 159:297-304. 10.1016/S0002-9440(10)61695-1, 1850401, 11438476.
55. Longo-Imedio MI, Longo N, Trevino I, Lazaro P, Sanchez-Mateos P. Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int J Cancer 2005, 117:861-865. 10.1002/ijc.21269, 15981210.
56. Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, Turner RR, Ye X, Bilchik AJ, Morton DL, Hoon DS. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 2006, 244:113-120. 10.1097/01.sla.0000217690.65909.9c, 1570598, 16794396.
57. Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J Clin Pathol 2007, 60:596-599. 10.1136/jcp.2005.032144, 1955073, 16522748.
58. Varney ML, Johansson SL, Singh RK. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 2006, 125:209-216.